Compare KORE & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KORE | TIL |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 74.7M |
| IPO Year | N/A | 2021 |
| Metric | KORE | TIL |
|---|---|---|
| Price | $4.89 | $7.09 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $5.00 | ★ $125.00 |
| AVG Volume (30 Days) | 50.4K | ★ 267.1K |
| Earning Date | 11-12-2025 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $285,408,000.00 | N/A |
| Revenue This Year | $1.26 | N/A |
| Revenue Next Year | $7.55 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.06 | N/A |
| 52 Week Low | $2.00 | $5.67 |
| 52 Week High | $5.03 | $42.79 |
| Indicator | KORE | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 59.25 | 32.23 |
| Support Level | $4.54 | $6.96 |
| Resistance Level | $5.03 | $7.29 |
| Average True Range (ATR) | 0.22 | 0.51 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 81.38 | 20.37 |
Kore Group Holdings Inc provides Internet of Things (IoT) solutions and services. In addition to providing critical services to customers globally, it enables them to manage, deploy, and scale their IoT applications and use cases. It offers connectivity services, location-based services, device solutions, and managed and professional services for the development and support of IoT technology for the Machine-to-Machine market. It derives revenue from IoT Connectivity services, IoT Solutions services, SIMs (IoT Connectivity), and IoT devices (IoT Solutions). Geographically, the company generates the majority of its revenue from the United States and the rest from other countries.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.